Company Profile

RepoCeuticals A/S is a clinical-stage biopharmaceutical company dedicated to the development of new, effective prophylactic and therapeutic uses of pharmaceutical agents with antioxidant and anti-inflammatory properties. This entails the repositioning and recombination of such substances for the prevention and treatment of conditions that have a significant impact on patients and the community and for which there are currently no preventive or other treatments, or for which there is a need for improved treatment.


The company operates chiefly in the cancer area, especially by developing new locally acting agents to prevent and treat the side effects that often result from the most widely used conventional treatments. The primary focus is on the serious side effects of radiation and cytotoxic chemotherapy for cancer in the thoracic and pelvic regions. As an expansion in 2019, the company initiated a new clinical project to alleviate the symptoms of low anterior resection syndrome (LARS).